4 Can't-Miss Health-Care Events to Watch For This Week

With the new year off to an amazingly bullish start and the JPMorgan Healthcare Conference now a thing of the past, we can turn our attention to four events -- two FDA drug decisions and two big earnings reports -- bound to turn investors' heads next week.

On Wednesday, biotech Santarus (NASDAQ: SNTS  ) will step in front of the firing squad and either receive an open-arms approval for its mild-to-moderate ulcerative colitis drug, Uceris, or the highly dreaded complete response letter. In trials, Uceris had a statistical benefit over the placebo in terms of percentage of patients reaching the primary endpoint, but combining the clinical and endoscopic trials after eight weeks produced less conclusive results. The PDUFA date for Uceris has already been pushed back 90 days (from Oct. 16 to Jan. 16), and it's uncertain whether an FDA approval is likely given the data. If I had to flip a coin, I'd bet on seeing a CRL.

On Thursday, NuPathe (UNKNOWN: PATH.DL  ) shareholders will be crossing their fingers and toes as the FDA rules on Zecuity (formerly NP101), a one-use transdermal migraine patch. This is a resubmission for NuPathe, which received a CRL in August 2011. Thankfully, the CRL had nothing to do with efficacy and was in relation to chemistry, manufacturing, and safety concerns. In phase 3 trials, 18% of patients treated with Zecuity were pain-free two hours after treatment, compared with just 9% for the placebo. Considering that NuPathe has patent protection on Zecuity through June 2028 and it appears to have addressed the FDA's previous issues, the chances of approval appear better than 50-50.

On the earnings front, investors can expect the smallest big pharma around, Forest Laboratories (NYSE: FRX  ) , and insurance heavyweight UnitedHealth Group (NYSE: UNH  ) , to report quarterly results on Tuesday and Thursday, respectively.

Forest Labs' quarterly figures should be particularly interesting since the company lost patent protection on its blockbuster depression drug, Lexapro, last year. Current Wall Street projections are counting on a 37% reduction in sales and a loss of $0.13 per share for Forest. This might be a rare case where the actual results matter very little as long as some of Forest's newer drugs show signs of life. Forest's Linzess, an irritable bowel syndrome and constipation treatment developed with Ironwood Pharmaceuticals (NASDAQ: IRWD  ) , and Tudorza, a bronchospasm inhibitor for those diagnosed with COPD, are two drugs to watch closely. Forest is a long way away from replacing Lexapro; and even if does find a combination of drugs to take its place, it'll then be losing its other revenue maker, Namenda, in 2015.

UnitedHealth Group's quarterly results should really set the tone for health-benefits sector as we head into what will be a very transitional 2014 with the full enactment of the Affordable Care Act. UnitedHealth has been adjusting its operations in anticipation of the pending changes since 2010, so I don't anticipate too many surprises. For the quarter, UnitedHealth is expected to grow sales by about 8.5% as EPS jogs higher by 2%. Given that UnitedHealth has handily trounced Wall Street's expectations over the past year and that it's been plumping up its payout to shareholders, I'm looking for this to be a very optimistic report.

What's really in store for health-benefit companies?
When President Obama was re-elected, shares of UnitedHealth and other health insurers fell immediately. Is Obamacare a death knell for health insurers, or is the market missing out on some of the opportunities the law presents? In this brand-new premium report on UnitedHealth, we take the long-term view, homing in on prospects for UnitedHealth in a post-Obamacare world. The report also comes with a full year of analyst updates to keep you covered as key news develops, so don't miss out -- simply click here now to claim your copy today.


Read/Post Comments (3) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 13, 2013, at 8:54 PM, tradingbasis wrote:

    "Uceris had a statistical benefit over the placebo in terms of percentage of patients reaching the primary endpoint, but combining the clinical and endoscopic trials after eight weeks produced less conclusive results. "

    To which treatment group are you referring? Are you confused between the Uceris 6Mg and the 9Mg dose studies?

    In December of 2011, Santaris announced that ".... in had In the 60 patients enrolled in the UCERIS 9 mg open-label study, the overall rate of remission was 25.0%; clinical improvement was 26.7%; endoscopic improvement was 40.0%; and symptom resolution was 33.3%.

    Although I do not expect a response from you on the above, I will take this opportunity to point out that Dr. Ted Love, an insider of Santarus, bought $2M of common stock in the open market just last month. Since Dr. Love is linked with R&D and the timing of his purchase was right after the FDA announced the of release proposed labeling later that month , I believe Dr. Love is giving slightly higher odds than a "coin-flip".

  • Report this Comment On January 14, 2013, at 1:25 AM, egobasher wrote:

    Might add that the FDA required the 6Mg dose study, the thought being that the drug would be used as maintenance on the lower dose once the patient is stable. It was expected that the lower dose would not have simular effect than the 9Mg dose. Listen to the conference calls.

  • Report this Comment On January 14, 2013, at 8:52 PM, Macsjv wrote:

    Good call on Santarus dummy! I have a bridge to sell you if your interested!!!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2193021, ~/Articles/ArticleHandler.aspx, 12/21/2014 3:15:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement